Cassava Sciences Announces New Patent Grant
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced it was granted U.S. Patent No. 10,760,052 on September 1,
2020. These patent claims are directed to inhibiting a
TLR4-mediated immune response though use of one or more unique
filamin A binding molecules.
Cassava Sciences’ lead drug candidate,
sumifilam, is a novel molecule. The Company’s patent protection in
the area of filamin-binding molecules currently runs through 2037,
plus extensions, and now includes seven issued patents plus related
patent filings and applications.
Sumifilam was discovered in-house. Cassava
Sciences owns worldwide development and commercial rights to its
research programs in Alzheimer’s disease, and related technologies,
without royalty obligations to any third-party.
Disease Alzheimer’s disease is a progressive brain
disorder that destroys memory and thinking skills. Currently, there
are no drug therapies to halt Alzheimer’s disease, much less
reverse its course. In the U.S. alone, approximately 5.8 million
people are currently living with Alzheimer’s disease, and
approximately 487,000 people age 65 or older developed Alzheimer’s
in 2019.1 The number of people living with Alzheimer’s disease is
expected to grow dramatically in the years ahead, resulting in a
growing social and economic burden.2
________________1, 2 Source: Alzheimer’s
Association. 2019 Alzheimer’s Disease Facts and Figures. Available
About Sumifilam (formerly,
PTI-125)Cassava Sciences’ lead therapeutic product
candidate is for the treatment of Alzheimer’s disease.
Sumifilam is a proprietary, small molecule (oral) drug that
restores the normal shape and function of altered filamin A (FLNA),
a scaffolding protein, in the brain. Altered FLNA in the brain
disrupts the normal function of neurons, leading to Alzheimer’s
pathology, neurodegeneration and neuroinflammation. The underlying
science is published in peer-reviewed scientific journals,
including Journal of Neuroscience, Neurobiology of Aging, Journal
of Biological Chemistry, Neuroimmunology and Neuroinflammation and
Journal of Prevention of Alzheimer’s Disease.
About SavaDxSavaDx is Cassava
Sciences’ investigational diagnostic to detect Alzheimer’s disease.
The goal of SavaDx is to make the detection of Alzheimer’s as
simple as getting a blood test, possibly years before the
appearance of any overt clinical symptoms.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and
develop innovations for chronic, neurodegenerative
conditions. Over the past 10 years, Cassava Sciences has combined
state-of-the-art technology with new insights in neurobiology to
develop novel solutions for Alzheimer’s disease. Both sumifilam and
SavaDx are substantially funded by research grant awards from the
National Institutes of Health.
For more information, please visit:
For More Information Contact:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.